Cargando…

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

BACKGROUND: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins involved in synapse functioning and immunity would be able to distinguish patients with Alzheimer’s disease (AD) and patients with mild cognitive impairment (MCI) from control subjects. METHODS: We in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duits, Flora H., Brinkmalm, Gunnar, Teunissen, Charlotte E., Brinkmalm, Ann, Scheltens, Philip, Van der Flier, Wiesje M., Zetterberg, Henrik, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389073/ https://www.ncbi.nlm.nih.gov/pubmed/29370833 http://dx.doi.org/10.1186/s13195-017-0335-x

Ejemplares similares

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
por: Clarke, Mica T. M., et al.
Publicado: (2019)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
por: Minta, Karolina, et al.
Publicado: (2021)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

CSF Presenilin-1 complexes are increased in Alzheimer’s disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2013)

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
por: Kvartsberg, Hlin, et al.
Publicado: (2018)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons
por: Nazir, Faisal Hayat, et al.
Publicado: (2018)

CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects
por: Xu, Chengai, et al.
Publicado: (2020)

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method
por: Öhrfelt, Annika, et al.
Publicado: (2011)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study
por: Milà-Alomà, Marta, et al.
Publicado: (2021)

Endo‐lysosomal protein concentrations in CSF from patients with frontotemporal dementia caused by CHMP2B mutation
por: Toft, Anders, et al.
Publicado: (2023)

Differential effects of familial Alzheimer’s disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity
por: Schilling, Sandra, et al.
Publicado: (2023)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
por: Duits, Flora H., et al.
Publicado: (2021)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
por: Hanes, Jozef, et al.
Publicado: (2020)

The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
por: Murray, Christina E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b9dbgnsgpsccco3iks3q0f3u5c